Trial Profile
TAS-102 and Bevacizumab as second line chemotherapy for colorectal cancer. Phase 2 trial
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2016
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TAS-CC2
- 02 Aug 2016 New trial record